Sign In
Buy ME
$0.606
+0 (+0%)
At Close: Sep 16, 2025
23andMe Holding Co. (ME) Q3 2023 Earnings Call Transcript
07:11pm, Wednesday, 08'th Feb 2023
23andMe Holding Co. (NASDAQ:ME ) Q3 2022 Earnings Conference Call February 8, 2023 4:30 PM ET Company Participants Wade Walke - VP, Investor Relations Anne Wojcicki - CEO & Co-Founder Joe Selsavage -
23andMe stock jumps more than 12% on raised 2023 guidance
04:50pm, Wednesday, 08'th Feb 2023
Shares of 23andMe Holding Co. ME, -0.40% rallied more than 12% in the extended session Wednesday after the genetics company raised guidance for 2023. 23andMe lost $92 million, or 20 cents a share, in
23andMe to Report FY2023 Third Quarter Financial Results
04:05pm, Thursday, 26'th Jan 2023
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access,
Adding 23andMe To My Tax Loss Basket
02:15am, Monday, 26'th Dec 2022
23andMe's stock price has been falling for several years now. But last week's drop seems to me to be driven by tax loss sellers who are indiscriminate about selling price; wanting only to harvest a ta
23andMe: Strong Genomics Quarter But Cash Burn Is Huge
10:05am, Monday, 21'st Nov 2022
23andMe Holding Co. is a DNA testing company which has genetic information on over 12 million customers. The company announced a strong Q2 FY23, beating both revenue and earnings estimates for growth.
23andme founder on the future of health care
09:00am, Saturday, 19'th Nov 2022
This segment originally aired on November 15, 2022. 23andMe Co-Founder and CEO Anne Wojcicki sits down with Yahoo Finance's Anjalee Khemlani at the HLTH conference to discuss the slowdown in growth, c
3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240%
10:27am, Wednesday, 09'th Nov 2022
Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Informa
23andMe Holding Co. (ME) Q2 2023 Earnings Call Transcript
10:32pm, Monday, 07'th Nov 2022
23andMe Holding Co. (NASDAQ:ME ) Q2 2023 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Wade Walke - Vice President-Investor Relations Anne Wojcicki - Chief Executive Office
I Bought 2 SPACs That Haven't Lived Up to Expectations -- Here's Why I'm Still Holding Them
06:18am, Friday, 28'th Oct 2022
These companies haven't performed as well as I thought they would, but I don't plan to sell.
23andMe to Report FY2023 Second Quarter Financial Results
04:05pm, Monday, 24'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people ac
2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years
10:15am, Friday, 21'st Oct 2022
They're both using unique and highly efficient approaches to developing and deploying their medicines.
23andMe to Present at Upcoming Investor Conferences
04:10pm, Wednesday, 12'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people ac
7 Best Reddit Stocks to Buy Now
06:35am, Wednesday, 05'th Oct 2022
Reddit's WallStreetBets forum took GameStop stock to unfathomable heights last year, ushering in the meme stock era. Though the retail trading frenzy has dulled considerably, the best Reddit stocks r
7 Undervalued Reddit Stocks to Buy Before Wall Street Catches On
05:00pm, Wednesday, 28'th Sep 2022
Reddit stocks have been so successful (or at least intriguing) that Reddit has quickly become an investing hub. The site has a huge community of investors and traders who use it as a platform for thei
23andMe: Disappointing Results Could Mean Potential Acquisition Target
01:36pm, Tuesday, 27'th Sep 2022
FQ1 revenue grew 9% yoy, however adjusted EBITDA loss reached $50 million and was down from the $27 million loss in the year-ago period. Full-year revenue guidance of $260-280 million was reiterated,
